Project Grant R01CA287083
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$437K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
This federal Project Grant award in the amount of $523,292 was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant funds research by the Dana-Farber Cancer Institute in Boston, Massachusetts to investigate a novel DNA repair defect in Ewing sarcoma, an aggressive form of bone and soft tissue cancer.
Specifically, the research aims to elucidate the molecular mechanisms by which the microhomology-mediated end-joining...
This $401,115 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), will fund Georgetown University's development and validation of a 3D bioengineered microfluidic platform (3D-BMP) to model Ewing sarcoma bone metastasis. The 3D-BMP will mimic the bone microenvironment to enable high-throughput genomic screening and identify key drivers of Ewing sarcoma's spread to bone. The project aims to: 1) optimize the 3D-BMP to faithfully...
This $514,405 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research by Sanford Research to investigate the role of cancer-dependent skeletal genes and pathways in the development and progression of osteosarcoma, a fatal bone tumor that primarily affects children. The research aims to elucidate the molecular mechanisms underlying the link between cancer-dependent skeletal pathways and osteosarcoma growth, with the goal of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $452,549.00 to Emory University to conduct research on targeting intrinsic and extrinsic features of MYC-driven osteosarcoma. The key objectives are to:
Comprehensively characterize and genetically perturb cross-species molecular features of MYC-hyperactivated human and murine osteosarcoma tumors to identify intrinsic and extrinsic signatures and cell-cell...
The U.S. Defense Health Agency awarded a $488,198 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Cleveland Clinic Foundation to support the development and evaluation of agents for a poor prognostic vertebrate model of Ewing sarcoma. The grant term runs from September 1, 2024 to August 31, 2027.
As a sub-award under this grant, Case Western Reserve University's Office of Research Administration Division (doing business as University Hospitals of...
This $540,090 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant, effective April 1, 2025, will fund research to characterize the biological basis of distinct epigenetic subtypes of osteosarcoma, a highly complex and genomically heterogeneous bone cancer, and identify subtype-specific vulnerabilities that could inform the...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $364,848 to the Dana-Farber Cancer Institute to investigate IGF2BP1 as a novel therapeutic target for Ewing's sarcoma, an aggressive pediatric bone cancer. The primary research activities involve using CRISPR-Cas9 gene editing to validate IGF2BP1 as an Ewing's sarcoma dependency, determining the molecular mechanisms underlying the IGF2BP1 dependency, and biochemically characterizing...
This Project Grant award issued by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), under the Cancer Treatment Research program (CFDA 93.395), provides $593,028 in funding to the Beckman Research Institute of the City of Hope to conduct research on the role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression. The 5-year award aims to define the critical role of IL-6/STAT3 signaling in tumor cell growth and metastasis, as...
The Defense Health Agency awarded Dana-Farber Cancer Institute a $712,001 Project Grant under the Military Medical Research and Development program to conduct research on understanding the role of DNA damage repair deficiency in Ewing sarcoma pathogenesis through integrative computational biology. The three-year award runs from September 1, 2023 through August 31, 2026.
Through this funding, Dana-Farber will utilize computational methods to analyze Ewing sarcoma tumor samples and related...
This $544,250 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of North Carolina at Chapel Hill to develop combination therapies to overcome chemoresistance in Ewing sarcoma. The research project, which has a performance period from August 15, 2024 to August 14, 2027, aims to advance innovative therapeutic approaches to improve outcomes for this rare and aggressive form of cancer....